Results

RDF/XMLNTriplesTurtleShow queryShare ▶
SubjectPredicateObject
http://purl.uniprot.org/citations/33737344http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/33737344http://www.w3.org/2000/01/rdf-schema#comment"

Background

Anti-programmed death (PD)-1 therapy has recently been used in recurrent or metastatic (R/M) nasopharyngeal carcinoma (NPC). The long-term survival and its biomarkers responding to anti-PD-1 treatment in patients with R/M NPC remain unclear.

Methods

Patients with R/M NPC were enrolled between March 2016 and January 2018 from two phase I clinical trials. The median follow-up period was 24.7 months. Eligible patients progressed on standard chemotherapy had measurable disease by Response Evaluation Criteria in Solid Tumor V.1.1. Non-obligatory contemporaneous tumor samples were collected for whole-exome sequencing. The primary outcome was objective response rate (ORR). Duration of response (DOR), progression-free survival (PFS), and overall survival (OS) were secondary outcomes assessed in all patients.

Results

Among 124 evaluable patients, anti-PD-1 therapy achieved an ORR of 29.8% and a durable clinical benefit rate of 60.5%. The median OS (mOS) was 17.1 months (95% CI 14.2 to 24.7), median PFS (mPFS) was 3.8 months (95% CI 3.4 to 6.0), and median DOR was 9.5 months. Significant OS benefit from treatment was observed in patients without liver metastasis (23.8 vs 13.3 months, p=0.006). Copy number deletion in genes encoding granzyme B or granzyme H (GZMB/H) was associated with poor treatment outcome (mPFS altered vs wildtype: 1.7 vs 3.6 months, p=0.03; mOS altered vs wildtype: 10.1 vs 18 months, p=0.012).

Conclusions

Anti-PD-1 treatment provided promising clinical benefit in pretreated patients with R/M NPC. Copy number loss in either GZMB or GZMH genes was associated with reduced survival."xsd:string
http://purl.uniprot.org/citations/33737344http://purl.org/dc/terms/identifier"doi:10.1136/jitc-2020-002014"xsd:string
http://purl.uniprot.org/citations/33737344http://purl.uniprot.org/core/author"Chen X."xsd:string
http://purl.uniprot.org/citations/33737344http://purl.uniprot.org/core/author"Huang Y."xsd:string
http://purl.uniprot.org/citations/33737344http://purl.uniprot.org/core/author"Hong S."xsd:string
http://purl.uniprot.org/citations/33737344http://purl.uniprot.org/core/author"Lin Q."xsd:string
http://purl.uniprot.org/citations/33737344http://purl.uniprot.org/core/author"Bao H."xsd:string
http://purl.uniprot.org/citations/33737344http://purl.uniprot.org/core/author"Ma Y."xsd:string
http://purl.uniprot.org/citations/33737344http://purl.uniprot.org/core/author"Zhang Y."xsd:string
http://purl.uniprot.org/citations/33737344http://purl.uniprot.org/core/author"Zhao H."xsd:string
http://purl.uniprot.org/citations/33737344http://purl.uniprot.org/core/author"Shao Y."xsd:string
http://purl.uniprot.org/citations/33737344http://purl.uniprot.org/core/author"Tang W."xsd:string
http://purl.uniprot.org/citations/33737344http://purl.uniprot.org/core/author"Zhang L."xsd:string
http://purl.uniprot.org/citations/33737344http://purl.uniprot.org/core/author"Wu X."xsd:string
http://purl.uniprot.org/citations/33737344http://purl.uniprot.org/core/author"Wang A."xsd:string
http://purl.uniprot.org/citations/33737344http://purl.uniprot.org/core/author"Yang Y."xsd:string
http://purl.uniprot.org/citations/33737344http://purl.uniprot.org/core/author"Fang W."xsd:string
http://purl.uniprot.org/citations/33737344http://purl.uniprot.org/core/date"2021"xsd:gYear
http://purl.uniprot.org/citations/33737344http://purl.uniprot.org/core/name"J Immunother Cancer"xsd:string
http://purl.uniprot.org/citations/33737344http://purl.uniprot.org/core/pages"e002014"xsd:string
http://purl.uniprot.org/citations/33737344http://purl.uniprot.org/core/title"Copy number loss in granzyme genes confers resistance to immune checkpoint inhibitor in nasopharyngeal carcinoma."xsd:string
http://purl.uniprot.org/citations/33737344http://purl.uniprot.org/core/volume"9"xsd:string
http://purl.uniprot.org/citations/33737344http://www.w3.org/2004/02/skos/core#exactMatchhttp://purl.uniprot.org/pubmed/33737344
http://purl.uniprot.org/citations/33737344http://xmlns.com/foaf/0.1/primaryTopicOfhttps://pubmed.ncbi.nlm.nih.gov/33737344
▶